中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2014年
10期
24-26
,共3页
王泓源%曹定睿%马晓燕%连梓敏
王泓源%曹定睿%馬曉燕%連梓敏
왕홍원%조정예%마효연%련재민
依托咪酯%HepG2细胞%肾上腺%免疫%细胞凋亡
依託咪酯%HepG2細胞%腎上腺%免疫%細胞凋亡
의탁미지%HepG2세포%신상선%면역%세포조망
Etomidate%HepG2 cells%Adrenal gland%Immunity%Apoptosis
目的:探讨不同浓度的依托咪酯是否具有直接诱导人肝癌HepG2细胞凋亡的作用,寻找依托咪酯临床治疗的新途径。方法人肝癌细胞株HepG2体外扩增培养备用,选取不同浓度的依托咪酯E1、E2、E3和对照组(空白),分别培养12h、24h、48h后观察。结果与空白对照组相比,培养12h、24h、48h后E1组、E2组人肝癌细胞株HepG2细胞凋亡率无明显差异(P>0.05),E3组凋亡率不断增加,具有显著性差异( P<0.05);随着培养时间的延长及浓度的不断增加,E1与E2组对比人肝癌细胞株HepG2细胞凋亡率无明显差异(t=1.732,P>0.05),E1与E3组对比人肝癌细胞株HepG2细胞凋亡率具有显著性差异(t=1.864, P<0.05),E2与E3组对比人肝癌细胞株HepG2细胞凋亡率具有明显差异(t=1.691,P<0.05)。结论依托咪酯在临床安全有效的浓度下不直接诱导人肝癌HepG2细胞的体外凋亡,浓度及时间达到一定峰值时可具有直接诱导人肝癌HepG2细胞体外凋亡的作用。
目的:探討不同濃度的依託咪酯是否具有直接誘導人肝癌HepG2細胞凋亡的作用,尋找依託咪酯臨床治療的新途徑。方法人肝癌細胞株HepG2體外擴增培養備用,選取不同濃度的依託咪酯E1、E2、E3和對照組(空白),分彆培養12h、24h、48h後觀察。結果與空白對照組相比,培養12h、24h、48h後E1組、E2組人肝癌細胞株HepG2細胞凋亡率無明顯差異(P>0.05),E3組凋亡率不斷增加,具有顯著性差異( P<0.05);隨著培養時間的延長及濃度的不斷增加,E1與E2組對比人肝癌細胞株HepG2細胞凋亡率無明顯差異(t=1.732,P>0.05),E1與E3組對比人肝癌細胞株HepG2細胞凋亡率具有顯著性差異(t=1.864, P<0.05),E2與E3組對比人肝癌細胞株HepG2細胞凋亡率具有明顯差異(t=1.691,P<0.05)。結論依託咪酯在臨床安全有效的濃度下不直接誘導人肝癌HepG2細胞的體外凋亡,濃度及時間達到一定峰值時可具有直接誘導人肝癌HepG2細胞體外凋亡的作用。
목적:탐토불동농도적의탁미지시부구유직접유도인간암HepG2세포조망적작용,심조의탁미지림상치료적신도경。방법인간암세포주HepG2체외확증배양비용,선취불동농도적의탁미지E1、E2、E3화대조조(공백),분별배양12h、24h、48h후관찰。결과여공백대조조상비,배양12h、24h、48h후E1조、E2조인간암세포주HepG2세포조망솔무명현차이(P>0.05),E3조조망솔불단증가,구유현저성차이( P<0.05);수착배양시간적연장급농도적불단증가,E1여E2조대비인간암세포주HepG2세포조망솔무명현차이(t=1.732,P>0.05),E1여E3조대비인간암세포주HepG2세포조망솔구유현저성차이(t=1.864, P<0.05),E2여E3조대비인간암세포주HepG2세포조망솔구유명현차이(t=1.691,P<0.05)。결론의탁미지재림상안전유효적농도하불직접유도인간암HepG2세포적체외조망,농도급시간체도일정봉치시가구유직접유도인간암HepG2세포체외조망적작용。
Objective To explore the different concentrations of etomidat whether directly induce the cell apoptosis to seek open up new ways of etomidate clinical treatment.MethodsHuman liver HepG2 cell line were amplificated cultivation for use in vitro, choose different concentrations of etomidate E1, E2 and E3 (blank) as control group.HepG2 were observed respectively after 12h, 24h, and 48h.With liver cancer HepG2 cell lines as target cells.Results Compared with the blank control group, 12h, 24h, 48h after culture E1 and E2 group liver HepG2 cell line apoptosis rate has no obvious difference(P>0.05), E3 group of apoptosis rate increased, and with significant difference (P<0.05); As the extension of incubation time and concentration increasing, E1 and E2 group compared with liver HepG2 cell line apoptosis rate have no significant difference(t=1.732,P>0.05), E1 and E3 group compared with liver HepG2 cell line apoptosis rate have significant difference(t=1.864,P<0.05),E2 and E3 group compared with liver HepG2 cell line apoptosis rate have obvious difference (t=1.691,P<0.05).Conclusion Etomidate with safe and effective concentrations in clinical are not directly induced HepG2 liver cancer cell apoptosis in vitro, but when concentration and time reach a certain peak can be directly induced the hepatocellular carcinoma HepG2 cells apoptosis in vitro.